Skip to main content
. 2012 Jan;86(2):919–929. doi: 10.1128/JVI.06150-11

Fig 2.

Fig 2

IFN-γ ELISPOT responses to 17 HIV CD8+ T-cell epitopes. (A) Four p24 capsid Gag optimal peptides screened in 9, 25, and 44 HLA-B*5702, HLA-B*5703, and HLA-B*5801 individuals, respectively, expressed as percent recognition of the peptide, ISW9 (ISPRTLNAW), KF11 (KAFSPEVIPMF), TW10 (TSTLQEQIAW), or QW9 (QATQDVKNW), indicated on the x axis. (B) Associations of IFN-γ ELISPOT responses to 18-mer peptides in HLA-B*5702-, HLA-B*5703-, and HLA-B*5801-expressing and HLA-B*57/58-negative individuals expressed as percent responders (y axis) to 13 18-mer peptides grouped according to 4 different HLA-B*57/58 expression levels, with the 18-mer peptide number and epitope abbreviation shown on the x axis. Significant P values between groups are shown above the bars for optimal peptides in panel A and are indicated by asterisks (***, P < 0.001; **, P < 0.001; and *, P < 0.01) for 18-mer peptide recognition compared to HLA-B*57/5801-negative individuals in panel B (Fisher's exact test).